In the Claims:

The current status of all claims is listed below and supercedes all previous lists of claims.

Please amend claims 1, 2, 10, 17, and 18 as follows.

1. (currently amended) A compound of formula I



I

wherein

R^1 represents a C_{1-4} alkoxy group optionally substituted by one or more fluoro, a C_{1-4} alkyl group optionally substituted by one or more fluoro, halo, cyano, a group OSO_2C_{1-4}alkyl wherein the alkyl group is optionally substituted with one or more fluorine atoms, a group NR^aR^b in which R^a and R^b independently represent H or a C_{1-4}alkyl group or R^a and R^b together with the nitrogen atom to which they are attached represent a saturated 3 to 7 membered heterocyclic ring optionally including an O, a group $CONR^cR^d$ in which R^c and R^d independently represent H or a C_{1-4}alkyl group or R^c and R^d together with the nitrogen atom to which they are attached represent a saturated 3 to 7 membered heterocyclic ring;

n represents 0, 1, 2 or 3;

R^2 represents a C_{1-4}alkyl group optionally substituted by one or more fluoro or a C_{1-4}alkoxy group optionally substituted by one or more fluoro, a group NR^aR^b in which R^a and R^b independently represent H or a C_{1-4} alkyl group or R^a and R^b together with the nitrogen atom to which they are attached represent a saturated 3 to 7 membered heterocyclic ring optionally including an O, a group $CONR^cR^d$ in which R^c and R^d independently represent H or a C_{1-4}alkyl group or R^c and R^d together with the nitrogen atom to which they are attached represent a saturated 3 to 7 membered heterocyclic ring;

m represents 0 or 1;

R^3 represents H or a C_{1-4} alkyl group;

L^1 represents a $(CH_2)_pC_{3-10}$ cycloalkyl$(CH_2)_q$ group in which p and q are independently selected from 0 and 1 and in which the cycloalkyl group may be monocyclic or bicyclic and optionally may be bridged provided that the two nitrogens bearing R^3 and R^4, respectively, are not linked to the same carbon atom, ~~and wherein one of the carbons may be replaced by O~~ or, alternatively, the group $-N(R^3)-L^1-$ ~~or the group L^1-$N(R^4)$ together~~ represent a saturated bicyclic heterocyclic ring containing from 2 to 9 carbon atoms and the nitrogen bearing R^3 or R^4 respectively;

R^4 represents H or a C_{1-4} alkyl group optionally substituted by one or more of the following: fluoro or C_{1-4} alkoxy optionally substituted by one or more fluoro;

L^2 represents an alkylene chain $(CH_2)_s$ in which s represents 1, 2 or 3 wherein the alkylene chain is optionally substituted by one or more of the following: fluoro or C_{1-4} alkyl;

~~or L^2 may also represent a 5-6 membered carbocyclic ring fused to R^5;~~

R^5 represents phenyl or naphthyl or a heterocyclic group selected from thienyl, furyl, pyridyl, pyrrolyl, quinolinyl, indolyl, benzofuranyl, benzo[*b*]thienyl, imidazolyl, benzimidazolyl, thiazolyl, thiadiazolyl, pyrimidinyl, pyrazolyl, oxazolyl, imidazo[1,2-*a*]pyridinyl, 5*H*-pyrrolo[2,3-*b*]pyrazinyl, 1*H*-pyrrolo[3,2-*c*]pyridinyl, 1*H*-pyrrolo[2,3-*c*]pyridinyl, 1*H*-pyrrolo[2,3-*b*]pyridinyl, *1H*-indazolyl, 1*H*-pyrrolo[3,2-*h*]quinolinyl, 1*H*-pyrrolo[3,2-*b*]pyridinyl, 2,1,3-benzothiadiazolyl, 2,1,3-benzoxadiazolyl, quinazolinyl or triazolyl wherein each R^5 is optionally substituted by one or more of the following: cyano, halo, a C_{1-4} alkyl group optionally substituted by one or more fluoro, a C_{1-4} alkoxy group optionally substituted by one or more fluoro, or by a group $S(O)_aR^y$ in which a is 0, 1 or 2 and R^y is phenyl optionally substituted by cyano, halo, a C_{1-4}alkyl group optionally substituted by one or more fluoro or a C_{1-4}alkoxy group optionally substituted by one or more fluoro, or by a group $O_z(CH_2)_wR^z$ in which z and w independently are 0 or 1 and R^z represents phenyl or a heterocyclic group selected from thienyl, pyridyl, thiazolyl, pyrazolyl, wherein each R^z is optionally substituted by one or more of the following: cyano, halo, a C_{1-4} alkyl group optionally substituted by one or more fluoro, or a C_{1-4}alkoxy group optionally substituted by one or more fluoro;

as well as optical isomers and racemates thereof as well as pharmaceutically acceptable salts, thereof; with the proviso that when

R^1 represents a C_{1-4}alkoxy group optionally substituted by one or more fluoro or a

C_{1-4}alkyl group optionally substituted by one or more fluoro; and

n represents 0 or 1; and

R^2 represents a C_{1-4}alkyl group optionally substituted by one or more fluoro or a C_{1-4}alkoxy group optionally substituted by one or more fluoro; and

m represents 0 or 1; and

R^3 represents H or a C_{1-4}alkyl group; and

L^1 represents a cyclohexyl group wherein the two nitrogens bearing R^3 and R^4, respectively, are linked to the cyclohexyl group either via the 1,3 or the 1,4 positions of the cyclohexyl group or L^1 represents a cyclopentyl group wherein the two nitrogens bearing R^3 and R^4, respectively, are linked to the cyclopentyl group via the 1,3 position of the cyclopentyl group; and

L^2 represents an alkylene chain $(CH_2)_s$ in which s represents 1, 2 or 3 wherein the alkylene chain is optionally substituted by one or more of the following: a C_{1-4}alkyl group; and

R^5 represents aryl wherein aryl means phenyl or naphthyl each of which is optionally substituted by one or more of the following: halo, a C_{1-4}alkyl group or phenyl, or

R^5 represents a heterocyclic group wherein the term heterocyclic group means thienyl, furyl, pyridyl, pyrrolyl, quinolinyl, indolyl, benzofuranyl or benzo[*b*]thienyl each of which is optionally substituted by one or more of the following: halo or a C_{1-4}alkyl group;

~~or L^2 represents a C_{5-6}cycloalkyl group which is fused to an R^5 which is phenyl or a heteroaryl group selected from thienyl, furyl or pyrrolyl;~~

then R^4 does not represent H or a C_{1-4}alkyl group; and excluding 1,4-anhydro-2,3,5-trideoxy-3-[[(3,4-dichlorophenyl)methyl]amino]-5-[(4-ethoxy-2-quinolinyl)amino]-D-erythro-pentitol.

2. (currently amended) A compound as claimed in claim 1 in which L^1 represents a monocyclic $-(CH_2)_pC_{5-6}(CH_2)_q-$ cycloalkyl group in which p and q are independently 0 or 1 wherein there are 3 carbon atoms between the two nitrogens bearing R^3 and R^4, respectively, ~~wherein one of the carbons of the cycloalkyl group may be replaced by O~~ or the group $-N(R^3)-L^1-$ ~~, or the group L^1-N(R^4), together~~ represent a saturated heterocyclic ring containing from 4 to 6 carbon atoms and the nitrogen bearing R^3 or R^4 respectively.

3. (previously presented) A compound of formula IA



IA

in which

R^1 represents chloro, fluoro, methoxy or a group NR^aR^b in which R^a and R^b independently represent H or a C_{1-4}alkyl group;

n represents 0, 1 or 2 and when n=1 the substituent is attached to either position 6 or 7;

R^2 represents a C_{1-4}alkyl group or a C_{1-4}alkoxy group optionally substituted by one or more fluoro, a group NR^aR^b in which R^a and R^b independently represent H or a C_{1-4}alkyl group or R^a and R^b together with the nitrogen atom to which they are attached represent a saturated 3 to 7 membered heterocyclic ring optionally including an O, a group $CONR^cR^d$ in which R^c and R^d independently represent H or a C_{1-4}alkyl group or R^c and R^d together with the nitrogen atom to which they are attached represent a saturated 3 to 7 membered heterocyclic ring;

m represents 0 or 1;

R^3 represents H;

A represents CH_2 and t is 0 or 1;

R^4 represents H;

L^2 represents CH_2, $C(CH_3)_2$ or CF_2; and

R^5 represents aryl or a heterocyclic group selected from thienyl, furyl, pyridyl, pyrrolyl, quinolinyl, indolyl, benzofuranyl, benzo[*b*]thienyl, imidazolyl, benzimidazolyl, thiazolyl, thiadiazolyl, pyrimidinyl, pyrazolyl, oxazolyl, imidazo[1,2-*a*]pyridine, 5*H*-pyrrolo[2,3-*b*]pyrazine, 1*H*-pyrrolo[3,2-*c*]pyridine, 1*H*-pyrrolo[2,3-*c*]pyridine, 1*H*-pyrrolo[2,3-*b*]pyridine, *1H*-indazole each of which is optionally substituted by one or more of the following: cyano, halo, a C_{1-4} alkyl group optionally substituted by one or more fluoro, a C_{1-4} alkoxy group optionally substituted by one or more fluoro, or by a group $S(O)_aR^y$ in which a is 0, 1 or 2 and R^y

is phenyl optionally substituted by cyano, halo, a C_{1-4}alkyl group optionally substituted by one or more fluoro or a C_{1-4}alkoxy group optionally substituted by one or more fluoro, or by a group $O_z(CH_2)_wR^z$ in which z and w independently are 0 or 1 and R^z represents phenyl or a heterocyclic group selected from thienyl, pyridyl, thiazolyl, pyrazolyl, wherein each R^z is optionally substituted by one or more cyano, halo, a C_{1-4} alkyl group optionally substituted by one or more fluoro, a C_{1-4}alkoxy group optionally substituted by one or more fluoro;

as well as optical isomers and racemates thereof as well as pharmaceutically acceptable salts thereof.

4. (previously presented) A compound of formula IB



IB

in which

R^1 represents H, methoxy, dimethylamino, chloro or fluoro;

R^2 represents H, a C_{1-4}alkyl group or a C_{1-4} alkoxy group optionally substituted by one or more fluoro, a group NR^aR^b in which R^a and R^b independently represent H or a C_{1-4}alkyl group or R^a and R^b together with the nitrogen atom to which they are attached represent a saturated 3 to 7 membered heterocyclic ring optionally including an O, a group $CONR^cR^d$ in which R^c and R^d independently represent H or a C_{1-4}alkyl group or R^c and R^d together with the nitrogen atom to which they are attached represent a saturated 3 to 7 membered heterocyclic ring;

R^3 represents H;

A represents CH_2 and t is 0 or 1;

R^4 represents H;

L^2 represents CH_2, $C(CH_3)_2$ or CF_2; and

R^5 represents 2-thienyl, 3-thienyl, indol-3-yl, 2-pyrrolyl, 5-pyrimidinyl, 4-thiadiazolyl,

pyrazolyl, or quinolin-2-yl each of which is optionally substituted by one or more of the following: cyano, halo, a C_{1-4} alkyl group optionally substituted by one or more fluoro, a C_{1-4} alkoxy group optionally substituted by one or more fluoro and in addition when R^5 is 2-thienyl it is optionally additionally substituted by pyridyl, 2-thienyl or 3-pyrazolyl each of which is optionally substituted by halo or a C_{1-4} alkyl group optionally substituted by one or more fluoro and when R^5 is indol-3-yl it is optionally additionally substituted by 1-(thiazol-5-yl)methyl which is optionally substituted by halo.

5. (previously presented) A compound of formula IC



IC

in which

R^1 represents H, methoxy, dimethylamino, chloro or fluoro;

R^2 represents H, a C_{1-4}alkyl group or a C_{1-4} alkoxy group optionally substituted by one or more fluoro, a group NR^aR^b in which R^a and R^b independently represent H or a C_{1-4}alkyl group or R^a and R^b together with the nitrogen atom to which they are attached represent a saturated 3 to 7 membered heterocyclic ring optionally including an O, a group $CONR^cR^d$ in which R^c and R^d independently represent H or a C_{1-4}alkyl group or R^c and R^d together with the nitrogen atom to which they are attached represent a saturated 3 to 7 membered heterocyclic ring;

R^3 represents H;

A represents CH_2 and t is 0 or 1;

R^4 represents H;

L^2 represents CH_2, $C(CH_3)_2$ or CF_2; and

R^5 represents 2-thienyl, 3-thienyl, indol-3-yl, 2-pyrrolyl, 5-pyrimidinyl, 4-thiadiazolyl, pyrazolyl, 1*H*-pyrrolo[3,2-b]pyridinyl or quinolin-2-yl each of which is optionally substituted by

one or more of the following: cyano, halo, a C_{1-4} alkyl group optionally substituted by one or more fluoro, a C_{1-4} alkoxy group optionally substituted by one or more fluoro and in addition when R^5 is 2-thienyl it is optionally additionally substituted by pyridyl, 2-thienyl or 3-pyrazolyl each of which is optionally substituted by halo or a C_{1-4} alkyl group optionally substituted by one or more fluoro and when R^5 is indol-3-yl it is optionally additionally substituted by 1-(thiazol-5-yl)methyl which is optionally substituted by halo.

6. (original) A compound as claimed in any one of claims 1 to 5 in which p is 0, q is 0 and L^1 is 1,3-cyclohexyl.

7. (previously presented) A compound as claimed in any one of claims 1 to 5 in which the two nitrogen atoms are in a trans orientation on the cycloalkyl ring.

8. (original) A compound as claimed in claim 7 wherein the absolute configuration of the cycloalkyl carbon atoms to which the nitrogen atoms are attached is S, S.

9. (previously presented) A compound according to any one of claims 1 to 5 in which R^5 represents one of the following:

1*H*-pyrrolo[3,2-*c*]pyridinyl;
1*H*-pyrrolo[2,3-*b*]pyridinyl;
1*H*-indazolyl;
1-imidazo[1,2-*a*]pyridinyl;
5*H*-pyrrolo[2,3-*b*]pyrazinyl;
1*H*-pyrrolo[3,2-*b*]pyridinyl;
1*H*-pyrrolo[3,2-*h*]quinolinyl;
2,1,3-benzothiadiazolyl; and
2,1,3-benzoxadiazolyl;

wherein each of these heterocycles is optionally substituted by one or more of the following: cyano, halo, a C_{1-4} alkyl group optionally substituted by one or more fluoro, a C_{1-4} alkoxy group optionally substituted by one or more fluoro, or by a group $S(O)_aR^y$ in which a is 0, 1 or 2 and R^y

is phenyl optionally substituted by cyano, halo, a C_{1-4}alkyl group optionally substituted by one or more fluoro or a C_{1-4}alkoxy group optionally substituted by one or more fluoro, or by a group $O_z(CH_2)_wR^z$ in which z and w independently are 0 or 1 and R^z represents phenyl or a heterocyclic group selected from thienyl, pyridyl, thiazolyl, pyrazolyl, wherein each R^z is optionally substituted by one or more of the following: cyano, halo, a C_{1-4} alkyl group optionally substituted by one or more fluoro, or a C_{1-4}alkoxy group optionally substituted by one or more fluoro.

10. (currently amended) A compound as claimed in any one of claims 1 to 5 in which L^1 represents a $(CH_2)_pC_{3-10}$ cycloalkyl$(CH_2)_q$ group in which p and q are independently selected from 0 and 1 and in which the cycloalkyl group may be monocyclic or bicyclic and optionally may be bridged provided that the two nitrogens bearing R^3 and R^4, respectively, are not linked to the same carbon atom, ~~and wherein one of the carbons may be replaced by O~~ or, alternatively, the group -N(R^3)-L^1- ~~or the group L^1-N(R^4) together~~ represent a saturated bicyclic heterocyclic ring containing from 2 to 9 carbon atoms and the nitrogen bearing R^3 or R^4 respectively; with the proviso that L^1 is not 1,4-cyclohexyl or 1,3-cyclopentyl.

11. (original) One or more of the following compounds:

N,*N*-dimethyl-2-[(3-{[(5-pyridin-2-yl-2-thienyl)methyl]amino}cyclohexyl)amino]-quinoline-4-carboxamide;

(1*S*,3*S*)-*N*-(6-chloro-4-methylquinolin-2-yl)-*N*'-[(1-methyl-1*H*-indol-3-yl)methyl]cyclohexane-1,3-diamine;

(1*S*,3*S*)-*N*-(6-fluoro-4-methylquinolin-2-yl)-*N*'-(3-thienylmethyl)cyclohexane-1,3-diamine;

(1*R*,3*R*)-*N*-(6-fluoro-4-methylquinolin-2-yl)-*N*'-(3-thienylmethyl)cyclohexane-1,3-diamine;

(1*S*,3*S*)-*N*-(6-fluoro-4-methoxyquinolin-2-yl)-*N*'-(3-thienylmethyl)cyclohexane-1,3-diamine;

(1*S*,3*S*)-*N*-(6-fluoro-4-methylquinolin-2-yl)-*N*'-[(1-methyl-1*H*-indol-3-yl)methyl]cyclopentane-1,3-diamine;

N-(6-chloroquinolin-2-yl)-*N*'-(3-thienylmethyl)cyclohexane-1,3-diamine;

N-(6-chloroquinolin-2-yl)-*N*'-[(1-methyl-1*H*-pyrrol-2-yl)methyl]cyclohexane-1,3-diamine;

N-(6-chloroquinolin-2-yl)-*N*'-(quinolin-3-ylmethyl)cyclohexane-1,3-diamine;

N^6,N^6-dimethyl-N^2-{3-[(3-thienylmethyl)amino]cyclohexyl}quinoline-2,6-diamine;

(1*S*,3*S*)-*N*-[(4-chloro-1-methyl-1*H*-pyrazol-3-yl)methyl]-*N*'-(6-methoxy-4-methylquinolin-2-yl)cyclopentane-1,3-diamine;

(1*S*,3*S*)-*N*-(6-methoxy-4-methylquinolin-2-yl)-*N*'-(1,2,3-thiadiazol-4-ylmethyl)cyclopentane-1,3-diamine;

(1*S*,3*S*)-*N*-(6-methoxy-4-methylquinolin-2-yl)-*N*'-[(5-pyridin-2-yl-2-thienyl)methyl]cyclopentane-1,3-diamine;

(1*S*,3*S*)-*N*-({1-[(2-chloro-1,3-thiazol-5-yl)methyl]-1*H*-indol-3-yl}methyl)-*N*'-(6-methoxy-4-methylquinolin-2-yl)cyclopentane-1,3-diamine;

(1*S*,3S)-*N*-(6-methoxy-4-methylquinolin-2-yl)-*N*'-({5-[1-methyl-5-(trifluoromethyl)-1*H*-pyrazol-3-yl]-2-thienyl}methyl)cyclopentane-1,3-diamine;

(1*S*,3*S*)-*N*-(2,2'-bithien-5-ylmethyl)-*N*'-(6-methoxy-4-methylquinolin-2-yl)cyclopentane-1,3-diamine;

N^4,N^4-dimethyl-N^2-{3-[(3-thienylmethyl)amino]cyclohexyl}quinoline-2,4-diamine;

N^4,N^4-dimethyl-N^2-[3-({[2-(phenylsulfonyl)-1,3-thiazol-5-yl]methyl}amino)-cyclohexyl]quinoline-2,4-diamine;

N^2-(3-{[(2,4-dimethoxypyrimidin-5-yl)methyl]amino}cyclohexyl)-N^4,N^4-dimethylquinoline-2,4-diamine;

3-(6-methoxy-4-methylquinolin-2-yl)-N-methyl-N-(3-thienylmethyl)-3-azabicyclo[3.2.1]octan-8-amine;

6-methoxy-4-methyl-*N*-[((1*R*,2*S*)-2-{[(1-methyl-1*H*-indol-3-yl)methyl]amino}cyclopentyl)methyl]quinolin-2-amine;

(1*S*,3*S*)- *N*-(6-fluoro-4-methylquinolin-2-yl)-*N*'-[(1-methyl-1*H*-pyrrolo[2,3-*b*]pyridin-3-yl)methyl]cyclopentane-1,3-diamine;

(1*S*,3*S*)-3-[({3-[(7-methoxy-4-methylquinolin-2-yl)amino]cyclopentyl}amino)methyl]-1-methyl-1*H*-indole-6-carbonitrile;

(1*S*,3*S*)- *N*-(6-fluoro-4-methylquinolin-2-yl)-*N*'-[(1-methyl-1*H*-indol-2-

yl)methyl]cyclopentane-1,3-diamine;

(1*S*,3*S*)- *N*-(6-fluoro-4-methylquinolin-2-yl)-*N*'-({1-[3-(trifluoromethyl)pyridin-2-yl]-1*H*-indol-3-yl}methyl)cyclopentane-1,3-diamine;

(1*S*,3*S*)- *N*-(6-fluoro-4-methylquinolin-2-yl)-*N*'-[(1-methyl-1*H*-indazol-3-yl)methyl]cyclopentane-1,3-diamine;

(1*S*,3*S*)-*N*-(7-methoxy-4-methylquinolin-2-yl)-*N*'-({1-[4-(trifluoromethyl)phenyl]-1*H*-pyrrol-3-yl}methyl)cyclopentane-1,3-diamine;

3-[({(1*S*,3*S*)-3-[(7-methoxy-4-methylquinolin-2-yl)amino]cyclopentyl}amino)methyl]-1-methyl-1*H*-indole-5-carbonitrile;

(1*S*,3*S*)-*N*-{[5-difluormethoxy-1*H*-indol-3-yl]methyl}-*N*'-(7-methoxy-4-methylquinolin-2-yl)cyclopentane-1,3-diamine;

(1*S*,2*S*,4*R*,6*S*)-*N*-(6-methoxy-4-methylquinolin-2-yl)-*N*'-(3-thienylmethyl)bicyclo[2.2.1]heptane-2,6-diamine;

(1*R*,2*S*,4*S*,6*S*)-*N*-(6-methoxy-4-methylquinolin-2-yl)-*N*'-(3-thienylmethyl)bicyclo[2.2.1]heptane-2,6-diamine;

(1*S*,2*S*,4*R*,6*S*)-*N*-(7-methoxy-4-methylquinolin-2-yl)-*N*'-[(1-methyl-1*H*-indol-3-yl)methyl]bicyclo[2.2.1]heptane-2,6-diamine;

6-methoxy-4-methyl-*N*-[(1*S*,2*R*)-2-({[(1-methyl-1*H*-indol-3-yl)methyl]amino}methyl)cyclopentyl]quinolin-2-amine;

(1*S*,3*S*)-*N*-(7-methoxy-4-methylquinolin-2-yl)-*N*'-[(1-methyl-1*H*-pyrrolo[3,2-*h*]quinolin-3-yl)methyl]cyclopentane-1,3-diamine;

(1S,3S)-N-(6-fluoro-4-methylquinolin-2-yl)-N'-[(1-methyl-1H-pyrrolo[2,3-c]pyridin-3-yl)methyl]cyclopentane-1,3-diamine;

(1S,3S)-N-(7-methoxy-4-methylquinolin-2-yl)-N'-[(1-methyl-1H-pyrrolo[3,2-b]pyridin-3-yl)methyl]cyclopentane-1,3-diamine;

(1S,3S)-N-(6-fluoro-4-methylquinolin-2-yl)-N'-(imidazo[1,2-a]pyridin-3-ylmethyl)cyclopentane-1,3-diamine;

(1*S*,3*S*)-*N*-{[5-(Benzyloxy)-1-methyl-1*H*-indol-3-yl]methyl}-*N*'-(7-methoxy-4-methylquinolin-2-yl)cyclopentane-1,3-diamine;

(1S,3S)-N-(7-Methoxy-4-methylquinolin-2-yl)-N'-[3-(trifluoromethoxy)benzyl]-

cyclohexane-1,3-diamine;

(1S,3S)-N-(2,1,3-Benzothiadiazol-4-ylmethyl)-N'-(7-methoxy-4-methylquinolin-2-yl)cyclohexane-1,3-diamine;

(1S,3S)-N-[(1,3-Dimethyl-1H-pyrazol-4-yl)methyl]-N'-(7-methoxy-4-methylquinolin-2-yl)cyclohexane-1,3-diamine; and

(1S,3S)-N-(2-Bromo-4-methoxybenzyl)-N'-(7-methoxy-4-methylquinolin-2-yl)cyclohexane-1,3-diamine;

and pharmaceutically acceptable salts thereof.

12. (canceled).

13. (previously presented) A pharmaceutical formulation comprising a compound as defined in any one of claims 1 to 5 or claim 11 and a pharmaceutically acceptable adjuvant, diluent or carrier.

14. (cancelled).

15. (previously presented) A method of treating obesity, a psychiatric disorder, anxiety, an anxio-depressive disorder, depression, bipolar disorder, ADHD, a cognitive disorder, a memory disorder, schizophrenia, epilepsy, a neurological disorder and a pain related disorder, comprising administering a pharmacologically effective amount of a compound as claimed in any one of claims 1 to 5 or claim 11 to a patient in need thereof.

16. (canceled).

17. (currently amended) A process for the preparation of a compound of formula I



I

comprising reacting a compound of formula II



II

in which

R^1 represents a C_{1-4} alkoxy group optionally substituted by one or more fluoro, a C_{1-4} alkyl group optionally substituted by one or more fluoro, halo, cyano, a group OSO_2C_{1-4}alkyl wherein the alkyl group is optionally substituted with one or more fluorine atoms, a group NR^aR^b in which R^a and R^b independently represent H or a C_{1-4}alkyl group or R^a and R^b together with the nitrogen atom to which they are attached represent a saturated 3 to 7 membered heterocyclic ring optionally including an O, a group $CONR^cR^d$ in which R^c and R^d independently represent H or a C_{1-4}alkyl group or R^c and R^d together with the nitrogen atom to which they are attached represent a saturated 3 to 7 membered heterocyclic ring;

n represents 0, 1, 2 or 3;

R^2 represents a C_{1-4}alkyl group optionally substituted by one or more fluoro or a C_{1-4}alkoxy group optionally substituted by one or more fluoro, a group NR^aR^b in which R^a and R^b independently represent H or a C_{1-4} alkyl group or R^a and R^b together with the nitrogen atom to which they are attached represent a saturated 3 to 7 membered heterocyclic ring optionally including an O, a group $CONR^cR^d$ in which R^c and R^d independently represent H or a C_{1-4}alkyl group or R^c and R^d together with the nitrogen atom to which they are attached represent a saturated 3 to 7 membered heterocyclic ring;

m represents 0 or 1;

R^3 represents H or a C_{1-4} alkyl group;

L^1 represents a $(CH_2)_pC_{3-10}$ cycloalkyl$(CH_2)_q$ group in which p and q are independently selected from 0 and 1 and in which the cycloalkyl group may be monocyclic or bicyclic and optionally may be bridged provided that the two nitrogens bearing R^3 and R^4, respectively, are not linked to the same carbon atom, ~~and wherein one of the carbons may be replaced by O~~ or, alternatively, the group $-N(R^3)-L^1-$ ~~or the group L^1-N(R^4) together~~ represent a saturated bicyclic heterocyclic ring containing from 2 to 9 carbon atoms and the nitrogen bearing R^3 or R^4 respectively; and

R^4 represents H or a C_{1-4} alkyl group optionally substituted by one or more of the following: fluoro or C_{1-4} alkoxy optionally substituted by one or more fluoro;

with a compound of formula III



III

in which R^5 is as previously defined and $L^{2'}$ represents a group which after reaction of compounds II and III gives L^2 on reduction, under reductive alkylation conditions.

18. (currently amended) A compound of formula II



II

in which

R^1 represents a C_{1-4} alkoxy group optionally substituted by one or more fluoro, a C_{1-4} alkyl group optionally substituted by one or more fluoro, halo, cyano, a group OSO_2C_{1-4}alkyl wherein the alkyl group is optionally substituted with one or more fluorine atoms, a group NR^aR^b in which R^a and R^b independently represent H or a C_{1-4}alkyl group or R^a and R^b together with the nitrogen atom to which they are attached represent a saturated 3 to 7 membered heterocyclic ring optionally including an O, a group $CONR^cR^d$ in which R^c and R^d independently represent H or a

C_{1-4}alkyl group or R^c and R^d together with the nitrogen atom to which they are attached represent a saturated 3 to 7 membered heterocyclic ring;

n represents 0, 1, 2 or 3;

R^2 represents a C_{1-4}alkyl group optionally substituted by one or more fluoro or a C_{1-4}alkoxy group optionally substituted by one or more fluoro, a group NR^aR^b in which R^a and R^b independently represent H or a C_{1-4} alkyl group or R^a and R^b together with the nitrogen atom to which they are attached represent a saturated 3 to 7 membered heterocyclic ring optionally including an O, a group $CONR^cR^d$ in which R^c and R^d independently represent H or a C_{1-4}alkyl group or R^c and R^d together with the nitrogen atom to which they are attached represent a saturated 3 to 7 membered heterocyclic ring;

m represents 0 or 1;

R^3 represents H or a C_{1-4} alkyl group;

L^1 represents a $(CH_2)_pC_{3-10}$ cycloalkyl$(CH_2)_q$ group in which p and q are independently selected from 0 and 1 and in which the cycloalkyl group may be monocyclic or bicyclic and optionally may be bridged provided that the two nitrogens bearing R^3 and R^4, respectively, are not linked to the same carbon atom, ~~and wherein one of the carbons may be replaced by O~~ or, alternatively, the group $-N(R^3)-L^1-$ ~~or the group L^1-$N(R^4)$ together~~ represent a saturated bicyclic heterocyclic ring containing from 2 to 9 carbon atoms and the nitrogen bearing R^3 or R^4 respectively; and

R^4 represents H or a C_{1-4} alkyl group optionally substituted by one or more of the following: fluoro or C_{1-4} alkoxy optionally substituted by one or more fluoro.

19. (previously presented) A compound selected from one or more of:

(1*S*, 3*S*)-Dibenzyl-cyclohexane-1,3-diylbiscarbamate; and

(1*S*, 3*S*)-Cyclohexane-1,3-diamine dihydrochloride.

20. (previously presented) A method of treating obesity, type II diabetes, or Metabolic syndrome comprising administering a pharmacologically effective amount of a compound as claimed in any one of claims 1 to 5 or claim 11 to a patient in need thereof.

21. (previously presented) A method of preventing type II diabetes comprising administering a pharmacologically effective amount of a compound as claimed in any one of claims 1 to 5 or claim 11 to a patient in need thereof.